ALTSTATION.IO

Becton, Dickinson and Company (BDX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$205.33

Change

-0.57%

Market Cap

$58.60B

Avg Volume

2.1M

Company Overview

Becton, Dickinson and Company (BDX) develops and manufactures a wide range of medical supplies, instruments, and diagnostic products. Their offerings include intravenous (IV) catheters, syringes, blood collection devices, and systems for medication management and laboratory diagnostics. Their customers range from hospitals and physicians to life science researchers and the pharmaceutical industry. Headquartered in Franklin Lakes, New Jersey, the company plays a crucial role in healthcare by providing essential tools and technology aimed at enhancing patient care and operational efficiency.

BDX is a market leader in the medical instruments and supplies segment, known for its innovative products and established reputation. Their competitive edge stems from a strong portfolio that addresses vital healthcare needs, extensive manufacturing capabilities, and a global distribution network. Key competitors include Medtronic, Abbott Laboratories, and Siemens Healthineers, all vying for share in the growing healthcare market. However, pricing pressures and regulatory challenges are constant threats that could impact their market position.

Currently, BDX is focused on growth through innovation and strategic partnerships. They are actively investing in advanced technologies, such as their collaboration with ChemoGLO to enhance safety in handling hazardous drugs. The company’s revenue for the fiscal year 2023 is projected to grow by approximately 5%, indicating a positive trend amid a challenging economic environment. They are also pivoting towards more connected devices and digital health solutions, positioning themselves to capture a larger share of the evolving healthcare landscape.

Key Financials

Market Cap

$58.60B

Revenue

$21.84B

EBITDA

$6.22B

Gross Margin

47.4%

Profit Margin

7.7%

Revenue Growth

8.3%

Total Cash

$649.00M

Total Debt

$20.02B

Free Cash Flow

$3.60B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

35.28

Forward P/E

13.07

Beta

0.28

52-Week High

$235.34

52-Week Low

$162.29

EPS

$5.82

50-Day Avg

$199.17

200-Day Avg

$187.12

Price/Book

2.31

Technical Analysis

Over the past 52 weeks, Becton, Dickinson and Company (BDX) has exhibited a moderate downward trend overall, culminating in a current price of $205.33, down 6.5% from the previous year. Key support is identified around $180, as this level has been tested multiple times since May, while resistance is evident at $210, where the price has struggled to maintain momentum. A notable ascending triangle pattern is forming in the chart, suggesting potential bullish activity if the price can break above the resistance at $210. Recently, momentum appears to be gaining, as the stock has been consistently testing the $210 mark, indicating potential upward movement if this level is breached. Currently, the price sits approximately 2.1% below its recent resistance, suggesting that a breakout could lead to a reversal in the overall trend and regain previous highs around $220.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Becton, Dickinson and Company (BDX) stock in the past week (February 1, 2026, to February 7, 2026):

1. Upcoming Q1 Earnings Report and Biosciences Spin-off Closure

Becton, Dickinson and Company is scheduled to report its fiscal first-quarter 2026 results before the market open on Monday, February 9, 2026. Analysts anticipate earnings per share (EPS) of $2.82 and revenues of $5.15 billion, representing a year-over-year decline for both metrics. This earnings release coincides with the expected closing of BD’s spin-off of its Biosciences & Diagnostic Solutions business, which is also set for February 9, 2026. The record date for this spin-off was February 5, 2026. Investors will be keenly watching management’s commentary and updated guidance for the reshaped company, which will operate as a pure-play medical technology business.

2. Citi Initiates “Buy” Rating Post-Spin-off

On February 3, 2026, Citi resumed coverage of Becton Dickinson with a “Buy” rating and set a price target of $233. The upgrade reflects Citi’s view that the sale of the Life Sciences Bioprocessing unit will transform BD into a more focused medical technology company with enhanced growth prospects. This move suggests a positive long-term outlook for the streamlined business.

Market Sentiment and Analyst Recommendations

Bull Case

The spin-off of Biosciences & Diagnostic Solutions on February 9 transforms BD into a pure-play medical device company with better margin potential and cleaner valuation comparables. Citi’s new “Buy” rating at $233 (13.4% upside from current price) signals institutional confidence in the post-spin structure. Revenue growth of 8.3% is solid for a $58.6B market cap company, and the analyst consensus target of $211.92 sits just 3.3% above current levels with a wide range suggesting upside to $270. The ascending triangle pattern breaking above $210 resistance could trigger momentum toward $220 highs. Product momentum is real: FDA approval of the EnCompass Breast Biopsy System, BD Research Cloud 7.0 launch, and sustainability partnerships show active innovation pipeline. The $649M cash position against $20.02B debt is manageable for a company generating $21.84B in revenue.

Bear Case

The 35.28 P/E ratio is elevated for a medical device company growing at 8.3%, leaving little room for disappointment. Q1 earnings expected February 9 are anticipated to show year-over-year declines in both EPS and revenue, which contradicts the growth narrative and could trigger selling into the spin-off completion. The stock is already down 6.5% over the past 52 weeks and has struggled to hold above $210 resistance, suggesting institutional hesitation about valuation. Debt load of $20.02B against $649M cash is tight, limiting financial flexibility if the spin-off creates operational challenges or if the separated company struggles. The 1% weekly decline heading into earnings shows investors are nervous, not excited. Spin-offs often underperform in the first 12 months as two smaller companies trade at lower multiples than the sum of their parts.

What to Watch

The February 9 Q1 earnings call and management guidance on the reshaped company are critical. Watch whether they raise FY2026 guidance or signal headwinds that justify the revenue decline. The stock needs to break and hold above $210 resistance to confirm the bullish ascending triangle pattern; failure to do so by end of February suggests the rally is dead. Track the stock performance of the spun-off Biosciences company in the first 30 days for clues about whether BD retained the right assets. Monitor the separated company’s gross margins and operating leverage over the next two quarters to validate whether the spin actually improves profitability. Watch for any M&A activity from BD management using the cleaner balance sheet as a currency. Analyst price target revisions in the two weeks after earnings will signal whether the $233 Citi target holds or gets repriced downward.

Analyst Consensus

BUY

Based on 12 analyst opinions

Low Target

$183.00

Mean Target

$211.92

High Target

$270.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

72,000

Earnings & Dividends

Next Earnings

Feb 09, 2026

EPS (Trailing)

$5.82

Dividend Yield

203.0%

Payout Ratio

71.5%

Frequently Asked Questions

Is BDX a good stock to buy?

Yes, Becton, Dickinson and Company (BDX) has an analyst recommendation of BUY with a target price of $211.92. The stock’s current price of $205.33 is positioned favorably within its 52-week range of $162.29 – $235.34.

What is BDX’s price target?

The current price target for BDX is set at $211.92 based on analyst projections. This represents a potential upside from the current trading price of $205.33.

Does BDX pay a dividend?

Yes, Becton, Dickinson and Company offers a dividend yield of 203.0%. This high yield makes it attractive for income-focused investors.

What is BDX’s P/E ratio?

BDX has a P/E ratio of 35.28 and a forward P/E of 13.07. The forward P/E suggests that the stock may be undervalued relative to its expected earnings growth.

What is BDX’s market capitalization?

Becton, Dickinson and Company has a market cap of $58.60 billion. This size indicates a stable company within the healthcare sector, providing a level of security for investors.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.